Valuation: Charles River Laboratories International, Inc.

Market Cap 13.32B 11.64B 10.94B 9.98B 18.74B 1,273B 18.74B 131B 50.67B 650B 50.02B 48.92B 2,096B P/E 2026 *
76.3x
P/E 2027 * 31.9x
Enterprise Value 15.43B 13.49B 12.67B 11.57B 21.71B 1,475B 21.71B 152B 58.7B 753B 57.95B 56.68B 2,429B EV / Sales 2026 *
3.95x
EV / Sales 2027 * 3.74x
Free-Float
95.58%
Yield 2026 *
-
Yield 2027 * -
09-17 Charles River Laboratories International Introduces Rapid Cell Banking Programs with Next-Generation Sequencing Characterization CI
09-17 Argus Research Adjusts Charles River Laboratories International PT to $330 From $250, Maintains Buy Rating MT
09-16 Charles River Laboratories to Provide Update on New Approach Methodologies Strategy on Investor Day, RBC Says MT
09-15 Charles River Laboratories International, Inc. Presents at 2026 Global Healthcare Conference, Sep-15-2026 09:40 AM
09-14 Charles River Laboratories International, Inc. Presents at Morgan Stanley 24th Annual Global Healthcare Conference, Sep-14-2026 10:00 AM
09-11 Evercore ISI Adjusts PT on Charles River Laboratories International to $320 From $300, Maintains Outperform Rating MT
09-08 Charles River Laboratories International Implements Endosafe Cartridge Technology Automated Manufacturing Suite CI
08-20 Charles River Laboratories International Insider Sold Shares Worth $599,711, According to a Recent SEC Filing MT
08-20 Charles River, Medigen Partner on Multivalent Enterovirus Vaccine MT
08-20 Charles River Laboratories International, Inc. and Medigen Vaccine Biologics Corp. Collaborate to Advance New Vaccine Development Programs Through Next Generation Sequencing CI
08-13 Charles River Laboratories International Insider Sold Shares Worth $1,038,657, According to a Recent SEC Filing MT
08-10 TD Cowen Adjusts PT on Charles River Laboratories International to $300 From $235, Maintains Buy Rating MT
08-10 Rothschild & Co Redburn Adjusts PT on Charles River Laboratories International to $318 From $241, Maintains Buy Rating MT
1 day+3.29%
1 week+5.94%
Current month+0.29%
1 month-3.18%
3 months+59.23%
6 months+82.97%
Current year+44.92%
1 week 270.88
Extreme 270.88
290.11
1 month 267.27
Extreme 267.27
303.3
Current year 146.2
Extreme 146.195
303.3
1 year 144.26
Extreme 144.26
303.3
3 years 91.86
Extreme 91.8609
303.3
5 years 91.86
Extreme 91.8609
460.21
10 years 67.2
Extreme 67.2
460.21
Manager TitleAgeSince
Chief Executive Officer 56 04/05/2026
Director of Finance/CFO 58 05/04/2026
Chief Tech/Sci/R&D Officer 45 11/01/2026
Director TitleAgeSince
Chairman 75 31/12/1999
Director/Board Member 56 04/05/2026
Chairman 69 04/05/2026
Date Insider Type Main position Quantity % Market Cap. Importance
25/08/26 Exercice

Director

100,683 0.2090%
19/08/26 Don

Chief Executive Officer

-528 0.0011%
19/08/26 Exercice

Executive/Senior Manager

6,117 0.0127%
Change 5-day change 1-year change 3-year change Capi.($)
+3.23%+5.94%+87.85%+44.82% 13.32B
+2.55%+4.77%+4.07%+32.02% 46.68B
+0.44%+0.53%+44.34%+36.41% 44.42B
+0.38%-5.39%+336.44%+546.08% 41.32B
-0.56%+4.94%+7.63%+90.79% 41.58B
-1.60%-0.17%+9.73%+43.63% 30.14B
+0.38%+1.58%+26.54%+159.71% 17.42B
-0.09%-1.89% - - 15.6B
+1.15%+7.46%+25.97%+43.93% 15.54B
-1.34%+11.36%-10.71% - 14.08B
Average +0.48%+3.04%+59.10%+124.67% 28.01B
Weighted average by Cap. +0.49%+1.85%+70.16%+139.07%

Financials

2026 *2027 *
Net sales 3.91B 3.42B 3.21B 2.93B 5.5B 374B 5.5B 38.55B 14.88B 191B 14.69B 14.37B 616B 4B 3.5B 3.29B 3B 5.63B 382B 5.63B 39.44B 15.22B 195B 15.02B 14.69B 630B
Net income 163M 142M 134M 122M 229M 15.54B 229M 1.6B 618M 7.94B 610M 597M 25.58B 431M 376M 354M 323M 606M 41.18B 606M 4.25B 1.64B 21.03B 1.62B 1.58B 67.8B
Net Debt 2.11B 1.85B 1.73B 1.58B 2.97B 202B 2.97B 20.82B 8.03B 103B 7.93B 7.76B 332B 1.63B 1.43B 1.34B 1.22B 2.29B 156B 2.29B 16.07B 6.2B 79.61B 6.12B 5.99B 257B
Logo Charles River Laboratories International, Inc.
Charles River Laboratories International, Inc. specializes in the development of products and services in the field of research and non-clinical drug development for pharmaceutical companies, government agencies and academic institutions. Net sales break down by activity as follows: - discovery and safety assessment services (59.8%): discovery services for the identification, screening and selection of main compounds for the development of new drug candidates, and in vivo and in vitro testing, including pharmacokinetic, bioanalytical, metabolic, toxicological and pathological studies, for the safety assessment of pharmaceutical products, medical devices, animal health products, chemical and agrochemical products and biocides; - development and sale of research models and related services (21.1%): mice, rats, immunodeficient models, rabbits, guinea pigs, hamsters, etc. The group also offers primary cells and specialized products (bioconservation products, freezing media for cell cultures, antigens, peptides, humanized mouse models, etc.) for the development and manufacture of new cell therapies ; - development of solutions used in drug manufacturing processes (19.1%): products and services for microbiological testing, in vitro testing, endotoxin testing, microbial identification, development, manufacturing of avian vaccines, etc. The group also offers contract manufacturing services for cell and gene therapies. Net sales break down by source of income between sales of services (80.9%) and sales of products (19.1%). Net sales are distributed geographically as follows: the United States (53.3%), Europe (27.5%), Canada (12.5%), Asia/Pacific (5.1%), and other (1.6%).
Employees
19,000
Date Price Change Volume
22/09/26 US$289.27 +3.68% 388,203
21/09/26 US$279.01 +0.34% 952,932
18/09/26 US$278.06 -1.28% 1,481,168
17/09/26 US$281.67 +3.02% 809,837
16/09/26 US$273.41 +0.19% 1,014,795
Trader
Investor
Global
Quality
ESG MSCI
AA
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
17
Last Close Price
279.01USD
Average target price
284.93USD
Spread / Average Target
+2.12%

Quarterly revenue - Rate of surprise

-40%: Exceptional extension
d
:
:
SEIZE THE OFFER!